Endpoint security versus productivity in the pharmaceutical industry: a false choice?

This resource is published by BlackBerry


Computing’s interviews with CIOs and CISOs consistently support the view that breaches are inevitable, and it is a consistent finding in both research and the recent history of the pharmaceutical sector in the UK.

Before anyone had heard the term COVID-19, the pharmaceutical industry was already a highly attractive target for attackers. It is an industry built on huge investments in the development of specific drugs, and the intellectual property (IP) on these drugs can be worth alot. However, since the industry has been front and centre in the global battle against COVID-19, both in terms of treatments and vaccine development. This has inevitably increased its value as a target.

The results shown in this research paper are drawn from a survey covering 100 IT professionals with responsibility for security strategy or implementation in pharmaceutical companies.

Download now to learn why the pharmaceutical industry does not have to choose between the securing of endpoints and the productivity of users – and security teams.


Related categories
Mobile Devices, Applications, Network, Malware, Endpoint Security, ERP, Embedded Systems, Email, SAN, Collaboration, Cloud, AIM




By requesting this resource you agree to our terms of use. All data is protected by our Privacy Notice. If you have any further questions please email dataprotection@headleymedia.com.

 By submitting this form, you are confirming you are an adult of 18 years or older and you agree to Blackberry contacting you with marketing-related emails or by telephone. You may unsubscribe at any time. Blackberry web sites and communications are subject to their Privacy Notice.Please agree to the conditions

Download Now

More resources from BlackBerry